Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purines and thymidylate, leading to reduced DNA and RNA production. This antiproliferative effect is most pronounced in rapidly dividing cells, such as immune cells and cancer cells.

The specific dose of Methotrexate Accord is determined by the prescribing clinician based on the indication, patient weight, renal function, and treatment goals. Dosing regimens vary widely between autoimmune disorders and oncology protocols, and the prescriber will tailor the schedule to each individual patient.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and loss. It is also not recommended while breastfeeding because it can be excreted in milk and may harm the infant. Effective contraception is required for women of child‑bearing potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Methotrexate is often considered the first‑line disease‑modifying antirheumatic drug because of its proven efficacy, oral and parenteral options, and cost‑effectiveness. Compared with biologic DMARDs, it has a broader therapeutic window but requires regular laboratory monitoring for liver and marrow toxicity. Choice depends on disease severity, patient comorbidities, and response to therapy.

Methotrexate Accord should be stored at controlled room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly sealed to maintain stability throughout its shelf life.

Methotrexate Accord is supplied as a parenteral solution and can be given via intra‑arterial, intramuscular, or intravenous injection, depending on the clinical indication and prescribing protocol. Administration is performed by qualified healthcare professionals in a controlled setting.

The most serious risks include severe liver toxicity, pulmonary fibrosis, and profound bone‑marrow suppression that can lead to life‑threatening infections or bleeding. Patients should be monitored closely for signs of hepatic dysfunction, respiratory symptoms, and abnormal blood counts, and treatment should be stopped if these events occur.

Methotrexate Accord is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with renal impairment or existing bone‑marrow disorders.